Literature DB >> 24372452

1974-2014: Reflections on the evolution of clinical pharmacology in the past 40 years and a message to our readers.

James M Ritter1.   

Abstract

Mesh：

Year:  2014        PMID： 24372452      PMCID： PMC3895341          DOI： 10.1111/bcp.12279

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

1.  The pitfalls in the development of biologic therapy.

Authors:  Ravinder N Maini; Marc Feldmann
Journal:  Nat Clin Pract Rheumatol       Date:  2007-01

Review 2.  Clinical pharmacology--providing tools and expertise for translational medicine.

Authors:  J K Aronson; A Cohen; L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

3.  Looking back: editors' pick of 2008.

Authors:  Y K Loke; A Somogyi; L D Lewis; M Schachter; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

4.  Progress with the polypill?

Authors:  J Michael Gaziano
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

5.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

6.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

7.  Prescribing aids for gentamicin.

Authors:  G E Mawer; R Ahmad; S M Dobbs; J G McGough; S B Lucas; J A Tooth
Journal:  Br J Clin Pharmacol       Date:  1974-02       Impact factor: 4.335

8.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Authors:  Kevin Fitzgerald; Maria Frank-Kamenetsky; Svetlana Shulga-Morskaya; Abigail Liebow; Brian R Bettencourt; Jessica E Sutherland; Renta M Hutabarat; Valerie A Clausen; Verena Karsten; Jeffrey Cehelsky; Saraswathy V Nochur; Victor Kotelianski; Jay Horton; Timothy Mant; Joseph Chiesa; James Ritter; Malathy Munisamy; Akshay K Vaishnaw; Jared A Gollob; Amy Simon
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

9.  Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.

Authors:  Esther Merki; Mark J Graham; Adam E Mullick; Elizabeth R Miller; Rosanne M Crooke; Robert E Pitas; Joseph L Witztum; Sotirios Tsimikas
Journal:  Circulation       Date:  2008-07-28       Impact factor: 29.690

10.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.